+

ES2166783T3 - Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii. - Google Patents

Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.

Info

Publication number
ES2166783T3
ES2166783T3 ES94926591T ES94926591T ES2166783T3 ES 2166783 T3 ES2166783 T3 ES 2166783T3 ES 94926591 T ES94926591 T ES 94926591T ES 94926591 T ES94926591 T ES 94926591T ES 2166783 T3 ES2166783 T3 ES 2166783T3
Authority
ES
Spain
Prior art keywords
viii
factor viii
factor
therapeutic agent
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94926591T
Other languages
English (en)
Inventor
Joseph Edward Curtis
Sam Leland Helgerson
Roger L Lundblad
Shu-Len Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Application granted granted Critical
Publication of ES2166783T3 publication Critical patent/ES2166783T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

EL FACTOR VIII ESTABILIZADO Y ACTIVADO SE UTILIZA COMO AGENTE TERAPEUTICO PARA TRATAR PACIENTES CON DEFICIENCIAS EN EL FACTOR VIII. ESTO INCLUYE PACIENTES DE HEMOFILIA A ASI COMO PACIENTES CON INHIBIDORES DEL FACTOR VIII QUE BLOQUEAN LA ACTIVIDAD HEMOSTATICA DEL FACTOR VIII. EL FACTOR VIII ESTABILIZADO Y ACTIVADO TAMBIEN SE PREPARARA EN UNA COMPOSICION TERAPEUTICA CON COADYUDANTES TERAPEUTICAMENTE ACEPTABLES.
ES94926591T 1993-09-13 1994-08-26 Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii. Expired - Lifetime ES2166783T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/120,894 US5576291A (en) 1993-09-13 1993-09-13 Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency

Publications (1)

Publication Number Publication Date
ES2166783T3 true ES2166783T3 (es) 2002-05-01

Family

ID=22393146

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94926591T Expired - Lifetime ES2166783T3 (es) 1993-09-13 1994-08-26 Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.

Country Status (10)

Country Link
US (1) US5576291A (es)
EP (1) EP0719154B1 (es)
JP (1) JPH09502714A (es)
AT (1) ATE207759T1 (es)
AU (1) AU686661B2 (es)
CA (1) CA2168332A1 (es)
DE (1) DE69428905T2 (es)
DK (1) DK0719154T3 (es)
ES (1) ES2166783T3 (es)
WO (1) WO1995007713A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003332A1 (en) * 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
PL203177B1 (pl) 1999-02-22 2009-09-30 Baxter Int Sposób liofilizacji wodnego preparatu farmaceutycznego
NZ516400A (en) * 1999-07-13 2004-02-27 Biovitrum Ab Stable factor VIII compositions
JP4643783B2 (ja) * 1999-12-24 2011-03-02 一般財団法人化学及血清療法研究所 フォンヴィルブランド因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
DE60232017D1 (de) 2001-12-21 2009-05-28 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
AU2003240438A1 (en) 2002-06-21 2004-01-06 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
BRPI0408439A (pt) * 2003-03-18 2006-04-04 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004103398A1 (en) * 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
WO2004112828A1 (en) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
CN102872451A (zh) 2003-08-14 2013-01-16 诺和诺德医疗保健公司 因子vii多肽类的含水液体药物组合物
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
RU2373953C2 (ru) * 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Стабилизированная композиция, содержащая полипептид фактора vii
JP5058160B2 (ja) * 2005-06-30 2012-10-24 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション 遺伝子発現の検出方法
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
AU2008245821B2 (en) * 2007-04-26 2013-07-04 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
US8183345B2 (en) 2007-11-01 2012-05-22 University Of Rochester Recombinant factor VIII having reduced inactivation by activated protein C
CA2742328C (en) 2008-11-07 2019-02-26 Baxter International Inc. Factor viii formulations
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
CN102741422B (zh) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
SI2822577T1 (sl) 2012-02-15 2019-07-31 Bioverativ Therapeutics Inc. Rekombinantni proteini faktorja VIII
CN111574632A (zh) 2012-02-15 2020-08-25 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3292407A4 (en) * 2015-05-06 2019-01-02 Prescient Medicine Holdings, LLC Development of novel automated screening method for detection of fviii inhibitors
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
IL308416B1 (en) 2016-12-02 2025-04-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2460305A2 (fr) * 1979-06-29 1981-01-23 Merieux Inst Procede de preparation d'un concentre de facteur viii
US4386068A (en) * 1980-02-26 1983-05-31 Cutter Laboratories, Inc. Antihemophilic factor concentrate and method for preparation
AT369263B (de) * 1980-08-27 1982-12-27 Immuno Ag Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates
US4649132A (en) * 1983-03-31 1987-03-10 Scripps Clinic And Research Foundation Treatment of Factor VIII inhibitors
US5101016A (en) * 1983-03-31 1992-03-31 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies to them
US4857635A (en) * 1983-03-31 1989-08-15 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies tof them
IE80638B1 (en) * 1983-03-31 1998-10-21 Scripps Research Inst Monoclonal antibodies to new factor VIII coagulant polypeptides
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
DK525384D0 (da) * 1984-11-05 1984-11-05 Nordisk Insulinlab Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
ATE72838T1 (de) * 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
US4769336A (en) * 1985-05-24 1988-09-06 Scripps Clinic And Research Foundation Treatment of factor VIII inhibitors
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1331157C (en) * 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US5171844A (en) * 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US4795806A (en) * 1987-07-16 1989-01-03 Miles Laboratories, Inc. Phospholipid affinity purification of Factor VIII:C
US4981951A (en) * 1988-04-14 1991-01-01 Miles Inc. Lectin affinity chromatography of factor VIII
US5149687A (en) * 1991-04-01 1992-09-22 United Technologies Corporation Method for making oriented bismuth and thallium superconductors comprising cold pressing at 700 MPa

Also Published As

Publication number Publication date
AU686661B2 (en) 1998-02-12
EP0719154A1 (en) 1996-07-03
WO1995007713A1 (en) 1995-03-23
DE69428905T2 (de) 2002-05-29
AU7638094A (en) 1995-04-03
EP0719154B1 (en) 2001-10-31
JPH09502714A (ja) 1997-03-18
US5576291A (en) 1996-11-19
ATE207759T1 (de) 2001-11-15
CA2168332A1 (en) 1995-03-23
DK0719154T3 (da) 2001-11-26
DE69428905D1 (de) 2001-12-06

Similar Documents

Publication Publication Date Title
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
UA41989C2 (uk) Фармацевтична композиція у вигляді гелю для лікування захворювань шкіри та спосіб лікування інфікованої шкіри
DE69613840D1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
DK1316308T3 (da) Transdermalt terapeutisk plaster med capsaicin og capsaicin-analoger
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
GR1002807B (el) Συστημα για την τοπικη θεραπεια της ακμης και μεθοδος παραγωγης του
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
UA41355C2 (uk) Засіб для лікування нейро-сніду
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
GB2188547B (en) Tamoxifen composition for the treatment of psoriasis.
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
ES2095578T3 (es) Composicion para el tratamiento de mastitis y metritis.
DE69739482D1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
DE69304266D1 (de) Zusammensetzung enthaltend Dibucaine-Hydrochlorid, ein Salicylat, Calciumbromid und ein antiphlogistisches steroid zur Schmerzbekämpfung
ES2044534T3 (es) Un metodo para la preparacion de una composicion tromboliticamente activa.
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载